Author/Authors :
Jalaeikhoo, Hassan Department of Blood and Research Center - AJA University of Medical Science, Tehran , Ahmadzadeh, Ahmad Hematology and Oncology Research Center - Vali Asr Hospital - Tehran University of Medical Science, Tehran , Toogeh, Gholamreza Hematology and Oncology Research Center - Vali Asr Hospital - Tehran University of Medical Science, Tehran , Charoosaei, Ramazan Hematology and Oncology Research Center - Vali Asr Hospital - Tehran University of Medical Science, Tehran , Keyhani, Manouchehr Hematology and Oncology Research Center - Vali Asr Hospital - Tehran University of Medical Science, Tehran , Haybar, Habib Emam Khomeini Hospital - Ahwaz Jundishapur University of Medical Science, Ahwaz , Valizadeh, Armita Department of Anatomy - Ahwaz Jundishapur University of Medical Science, Ahwaz , Yadollahzadeh, Mehdi Department of Internal Medicine - Shahid Beheshti University of Medical Sciences, Tehran
Abstract :
Background: The present study reported a six-year follow up of patients with chronic myeloid leukemia who were on imatinib therapy.
Methods: We performed a retrospective study on a total of 417 patients diagnosed with chronic-phase, Philadelphia-positive (Ph+) chronic
myeloid leukemia within six months before study entry. Patients were eligible for the study if they were between 18 and 70 years of age.
Enrolled patients were treated at an initial dose of 400 mg of imatinib.
Results: The mean age of 417 patients was 40.9±14.5 years; 220 (52%) were men and 197 (47.2%) were women. Complete hematologic
response at three months occurred in 99% of patients, 221 (53%) before four weeks and 196 (47%) after four weeks. Adverse events occurred
in 17 (4.1%) of patients, relapse in 46 (11%) and death in 31 (7.4%) of our studied population. At 72 months, the estimated rate of
overall survival rate was 89%.
D iscussion: Our finding s showed the efficacy and safety of imatinib mesylate among Iranian patients with chronic myeloid leukemia by
hematological and molecular response.
